Shenghe Bio-B (02898) is listed for the first timespacepinball, shares rose 7spacepinball.11%, currently quoted at HK$14.46, with a turnover of HK$15.4099 million.

According to Frost Sullivan, Shenghe Bio is one of the world's leading companies in developing antibody cytokine products and one of the few pioneers with the fastest clinically progressing antibody cytokine candidate products. Public information shows that Shenghe Bio's three core products include two antibody cytokines and one ADCC-enhancing antibody. Two antibody cytokines, IAP0971 and IAE0972, were developed based on the company's AICTM platform. ADCC-enhanced antibody IAH0968 was developed based on the company's ADCC-enhanced antibody platform (AEATM platform).